# CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

> **NCT03393611** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 14 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Leukemia, Relapsed Adult Acute Myeloid
- Myelodysplastic Syndromes, Previously Treated

## Interventions

- **DRUG:** CPX-351
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Rabbit Anti-Human T-Lymphocyte Globulin
- **BIOLOGICAL:** Haplo-Cord Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT03393611
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-30
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-11-18
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393611, "CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03393611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*